Rezurock Tablet
NDC Package 79802-200-30

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Rezurock (belumosudil) tablets is rEZUROCK is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy. This formulation utilizes a tablet delivery system. Marketed by Kadmon Pharmaceuticals, Llc, this product is identified by NDC 79802-200 and is authorized under FDA application NDA214783.

Identification & Billing

NDC Package Code
79802-200-30
Package Description
1 BOTTLE in 1 CARTON / 30 TABLET in 1 BOTTLE
Product Code
79802-200
11-Digit Billing Format
79802020030
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Rezurock
Non-Proprietary Name
Belumosudil
Substance Name
Belumosudil
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
BELUMOSUDIL 200 mg/1
Usage Information
REZUROCK is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.

Regulatory & Marketing

Labeler Name
Kadmon Pharmaceuticals, Llc
Product Type
Human Prescription Drug
FDA Application #
NDA214783
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
07-16-2021
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J7599
Source: PDAC
IMMUNOSUPPRESSIVE DRUG, NOT OTHERWISE CLASSIFIED
HCPCS Dosage 0
Units / Pkg

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 79802-200-30 identifies a specific commercial package of 1 bottle in 1 carton / 30 tablet in 1 bottle of Rezurock, a human prescription drug labeled by Kadmon Pharmaceuticals, Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This tablet is formulated for oral use and contains belumosudil as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Kadmon Pharmaceuticals, Llc on July 16, 2021. The current certification is valid through December 31, 2027.

How is this Kadmon Pharmaceuticals, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 79802020030. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
79802-200-30
11-Digit CMS (5-4-2)
79802-0200-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.